Akademik Veri Yönetim Sistemi
Journal of Research in Pharmacy, cilt.30, sa.2, ss.660-670, 2026 (ESCI, Scopus, TRDizin)
Type 2 diabetes mellitus (T2DM) is increasingly recognized as a significant risk factor for cognitive decline and Alzheimer's disease (AD), yet the effects of antidiabetic agents on diabetes-related neurodegeneration are not fully understood. This study aimed to investigate the effects of the non-selective sodium-glucose cotransporter (SGLT) inhibitor phlorizin and the selective SGLT2 inhibitor dapagliflozin on metabolic and cognitive parameters in a rat model of T2DM-associated cognitive impairment (T2DM-CD). Sprague-Dawley rats were fed a high-fat diet and administered low-dose streptozotocin, followed by treatment with dapagliflozin, phlorizin, metformin, or rivastigmine for four weeks. Blood glucose, body weight, locomotor activity, and recognition memory were assessed using metabolic and behavioural tests. The T2DM-CD model showed hyperglycaemia without changes in locomotor activity and significant deficits in recognition memory. Dapagliflozin and phlorizin treatments significantly reduced blood glucose and improved recognition memory compared to the T2DM-CD model. Rivastigmine improved cognitive performance without affecting glycaemic control, while metformin improved glycaemic status and provided modest cognitive improvement. These findings suggest that SGLT inhibition may alleviate cognitive deficits in the T2DM-CD model and that SGLT inhibitors may exert beneficial effects on diabetes-related cognitive dysfunction through both metabolic and central mechanisms.